GREENVILLE, S.C., May 30 /PRNewswire-FirstCall/ -- Signalife, Inc. announces that the prototype of its event monitor has been developed and tested. This event monitor will include Signalife’s award winning and patented amplification technology. It is a single channel event monitor that will allow superior detection of symptomatic arrhythmias as the fidelity of its signal is unsurpassed.
Event monitors allow physicians to monitor patients over a longer period of time in an attempt to correlate the patient’s symptoms to a specific arrhythmia and to determine the proper course of treatment. Event monitors can be used to detect and confirm various arrhythmias as well as ischemic episodes. Signalife looks forward to offering physicians another commercial product to better monitor a patient’s cardiovascular health. The company already sells its first commercial product, the Fidelity 100, to physicians and hospitals as a 12 lead, real time ambulatory ECG.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Claire M. LaFrance of Signalife, +1-864-233-2300
Web site: http://www.Signalife.com/